Table 7.
Thyroid Structural Features in Lipodystrophy and INSR Mutation Groups Based on Leptin Treatment
| Never on Leptin (n = 32) | On Leptina (n = 60) | P Value | |
|---|---|---|---|
| Age, y | 32 ± 18.5 (7–66) | 30 ± 18 (2–80) | 0.9 |
| BSA, m2 | 1.65 ± 0.3 (0.77–2.12) | 1.62 ± 0.35 (0.47–2.19) | 0.7 |
| Thyroid volume, mL | 9.4 ± 6 (2.3–28.2) | 11 ± 6.8 (1.5–41.2) | 0.2 |
| Echogenicity | 0.3 | ||
| Homogeneous, n, % | 12, 37.5 | 37, 62 | |
| Heterogeneous, n, % | 20, 62.5 | 23, 38 | |
| Cysts | 0.5 | ||
| Yes, n, % | 18, 56 | 38, 63 | |
| No, n, % | 14, 44 | 22, 38 | |
| Nodules | 0.1 | ||
| Yes, n, % | 7, 22 | 23, 38 | |
| No, n, % | 25, 78 | 37, 62 | |
| Number of nodules/patients | 11/7 | 45/23 | |
| Peripheral/rim calcifications, n, % | 2, 18.2 | 11, 24.4 | 0.9 |
a
One patient each in the INSR mutation and lipodystrophy groups were previously treated with leptin (duration of 1 to 4.3 y) but not taking leptin at the time of US.